Biotechnology is set to become one of the most dynamic areas for venture capital investment in 2026. Following a period of caution, investors are returning to the industry, focusing on companies that combine deep science, digital technology, and real clinical value.

The current state of the biotechnology market

Therapies for rare and orphan diseases

The orphan therapy market has become one of the most dynamic areas of biotechnology. Orphan diseases affect fewer than 1 in 2,000 people, but there are more than 7,000 of them. This creates niche but extremely profitable opportunities for startups and venture investors.

The average cost of developing an orphan drug is lower than that of mass-market medications, and the potential return on investment is higher due to less competition and faster access to regulatory approval. Agencies such as the FDA or EMA often provide fast-track procedures, tax incentives, and market exclusivity for periods ranging from seven to ten years.

However, conducting clinical trials remains challenging: the small number of patients makes it difficult to obtain statistically valid results, and treatment costs can reach hundreds of thousands of dollars. Therefore, partnerships with patient foundations, charities and pharmaceutical giants have become standard in the business models of such startups.

Investors view orphan biotechnology as a promising industry due to its small but scalable user base, high margins and stable revenues. It is set to be one of the most interesting areas in the venture portfolio over the next decade.

Digital health, diagnostic platforms, biosensors, and digital biology

Digital biology is where biotechnology and artificial intelligence meet. It is transforming the way we measure, predict and treat health conditions. For instance, diagnostic platforms and biosensors enable us to monitor the body's condition in real time, establishing a novel approach to preventive medicine.

Investors are attracted to this segment because of its speed: product development requires less time and capital than traditional pharmaceuticals. Startups operate on a software as a service (SaaS) model, offering analytics subscriptions, remote monitoring and integration with hospitals.

Barriers include data regulation (GDPR, HIPAA) and user trust. Those companies that can guarantee the security of personal information and the clinical accuracy of their algorithms will be successful.

Regional opportunities and growth platforms

Biotechnology centres are gradually expanding beyond the United States and Western Europe. By 2025, investment will increasingly be directed towards Asia, the Middle East and Eastern Europe. Thanks to government support, favourable taxation, and the availability of highly skilled personnel, Singapore, South Korea, Israel and Poland are becoming magnets for R&D laboratories and startups.

European investors are seeking opportunities in countries with lower research costs but high scientific potential. Ukraine, for instance, boasts a robust molecular biology programme and a wealth of IT talent, paving the way for the development of bioinformatics hubs.

In the US, there is a concentration around 'bioeconomic clusters' such as Boston-Cambridge, the Bay Area and the Texas Bio Corridor. However, new platforms such as BioValley in Switzerland and Biopolis in Singapore offer a more integrated ecosystem, incorporating everything from laboratories to venture funds and accelerators.

Investors are becoming more flexible: capital from the US can be used for production in Eastern Europe and research in India, for example. Regional diversification is becoming a key competitive advantage in the global bioeconomy, as well as a way to reduce risk.

Funding strategies and models that transform the landscape

Asset-centric vs. platform-centric models

In biotechnology, there are two main business models: asset-centric, which focuses on a specific product or molecule, and platform-centric, which creates a technological base for many products.

The asset-centric model is attractive to investors because of its simplicity: there is one goal, one asset and one exit. This model offers a quick path to monetisation, particularly when a startup is developing a specific drug or diagnostic test. However, this model has one key limitation: once the asset has been sold, the company loses its main source of value.

The platform-centric model is a longer-term strategy. It requires more capital, but it creates a foundation for the development of numerous future drugs or technologies. Moderna, for example, built a platform based on mRNA and became a giant thanks to the scalability of its approach.

Hybrid forms of financing: mixed funds, royalties, credit structures and corporate ventures

Drug development is a lengthy, costly and risky process, which is why an increasing number of stakeholders are turning to hybrid models. This combination of venture, credit and corporate capital enables more flexible risk management.

One of the key instruments has become royalty financing, whereby the investor receives a share of future revenue from drug sales, rather than from company capital. This approach reduces ownership dilution and attracts institutional investors seeking stable cash flow.

Venture debt structures are also becoming increasingly popular among biotech startups that have already achieved positive clinical results, but have not yet become profitable. These structures enable companies to avoid issuing additional shares and maintain control.

Corporate venture funds are another source of capital, gaining momentum. Large pharmaceutical companies such as Novartis, Roche, and Johnson & Johnson are actively investing in startups to integrate promising technologies as early as possible.

Mixed funds combining private, public and corporate capital are forming a new type of innovative financing — a strategically motivated cycle that lasts longer than the usual VC cycle. Consequently, the biotechnology ecosystem is shifting towards more sustainable financial models where risks are distributed among several partners and rewards become more predictable.

Early-stage investments: sizes of pre-seed and seed rounds, and increased requirements for proof of concept

By 2025, the average pre-seed round in biotechnology is expected to reach between $500,000 and $800,000, while seed rounds are expected to range from $2 million to $5 million. However, the most important factor is the quality of the scientific and commercial foundation.

Investors expect startups to provide more than just ideas from the laboratory; they also require proof of concept (PoC), such as preliminary experimental results and validated models. Often, they also demand collaboration with academic institutions. Investors are also increasingly demanding a demonstration of market strategy — namely, how the company plans to scale its research into a business.

The role of angel investors with STEM experience who can evaluate the scientific depth of a project is growing. Additionally, microfunds that specialise specifically in pre-seed biotechnology are emerging, such as IndieBio and Petri.

Early investments are becoming a test of a startup's readiness for the big market, not just a start. Those who can convincingly prove their concept receive not only funding, but also the trust of the venture market — the most valuable asset in this industry.

Exit strategies: Initial public offering (IPO), mergers and acquisitions (M&A) and licensing

An IPO remains an attractive option for large companies that have reached clinical phase III or have a platform with multiple assets. However, the associated regulatory complexity, profitability requirements and market volatility can make this path costly and risky.

Conversely, mergers and acquisitions (M&As) enable startups to exit more quickly and gain access to the resources of large pharmaceutical companies. Companies such as Pfizer and Amgen are actively acquiring small, proven biotechnology companies. For venture capitalists, this means an early exit with less risk.

Another option is licensing, whereby a startup sells the rights to develop or commercialise a drug, but retains a portion of the royalties. This flexible model is particularly suited to asset-centric companies that create a single molecule or technology.

The modern exit strategy is more like a mosaic, combining IPOs, partial licences and strategic alliances. The main thing for investors is not only to sell, but also to build an ecosystem in which each exit creates new reinvestment opportunities.

Risks and barriers to consider

Regulatory hurdles and the long road to clinical trials

The regulatory system is the main filter separating science from business in biotechnology. Every new drug must undergo a complex approval process that can take seven to twelve years. This is the main factor shaping an investor's time horizons.

The process includes preclinical studies and three phases of clinical trials, followed by post-marketing monitoring. Each phase requires not only financing but also strict adherence to Good Clinical Practice (GCP) standards. Any violation can set the process back by years.

For startups, the biggest challenge is the time and money invested before the first commercial results are achieved. Therefore, investors often look for companies that have already obtained Investigational New Drug (IND) approvals or fast-track status.

In addition, there is growing pressure from ethics committees, particularly in the field of genetic engineering. FDA or EMA decisions may depend not only on scientific data, but also on public perception of the technology.

Although there are now initiatives for accelerated approval of breakthrough therapies, these only apply to a limited number of projects. For other biotechnology companies, the regulatory environment remains a major obstacle, requiring strategic planning from the day a startup is founded.

Cost, drug development times and high uncertainty

Developing a new drug is one of the most expensive and risky forms of innovation in the world. On average, it costs over $2 billion to create drugs that successfully reach the market, and the process takes 10–15 years.

This is due not only to the complexity of the science but also to the high dropout rate. Out of a thousand molecules under investigation, only one passes all clinical phases. The rest are stopped due to toxicity, ineffectiveness, or issues with scaling up production.

Investors face long periods without liquidity. Unlike technology startups, there are no quick exits here. This requires a special type of capital — patient capital.

Companies are trying to reduce risks by using artificial intelligence-based modelling, conducting digital clinical trials, and collaborating with CROs (Contract Research Organisations) to optimise costs.

However, even with all these innovations, uncertainty remains at the heart of the industry. The success or failure of a single molecule can change the balance of the entire market. This is why biotech investments are considered the riskiest in the world of venture capital.

Problems with reproducibility and safety

One of the most challenging issues in modern biotechnology is the reproducibility of results. Many studies, even those published in leading journals, cannot be replicated by other laboratories. For venture capitalists, this is a sign of high risk: if the underlying data cannot be verified, the entire commercial potential could evaporate overnight. Modern funds are increasingly requiring confirmation of results in independent centres before providing funding.

The problem is exacerbated by the fact that, in the early stages, startups often work with small data samples or insufficiently standardised protocols. Automated data collection systems, machine learning to verify results and blockchain solutions to ensure the transparency of scientific records are therefore becoming increasingly commonplace.

Safety is also becoming a cornerstone, with regulators tightening requirements for biomaterials, GMO technologies and artificial DNA synthesis.

Investors are not only interested in scientific breakthroughs but also in a company's ability to adhere to the principles of scientific integrity. Funds specialising in deep tech are establishing internal scientific councils to evaluate the reliability of data. This is not just a formality, but a real necessity in an environment where mistakes can cost billions. Today, biotech is about more than just innovation; it's about striking the right balance between science, ethics, and evidence.

Competition, overvaluation and the 'bubble effect'

Following rapid growth in 2020–21, the biotechnology market was hit by overvaluation. Many startups received overly high valuations at the seed or Series A stage, despite having no real proof of effectiveness. This created a 'bubble' effect, which began to gradually deflate in 2024–25. Investors became more cautious, and companies became more pragmatic in their forecasts.

Competition among biotech companies is extremely fierce today. Thousands of teams are working on similar targets or technologies. Therefore, the decisive factors are not only the scientific idea itself, but also the speed with which it can be transitioned to clinical trials, the establishment of strategic partnerships, and the quality of management. Investors are no longer looking for pure scientific discoveries — they are looking for business models that can survive in a highly competitive market.

Overvaluation is particularly risky for startups planning an IPO or M&A. Overvaluation in the early stages often makes exiting difficult, as buyers are unwilling to pay for unrealistic expectations. A return to a healthier valuation logic based on evidence, patent portfolio and scalability potential is expected in 2026. The biotechnology market is finally learning to distinguish between empty promises and sustainable technologies.

Forecasts for 2026 and beyond

Following several years of strategic reviews and the elimination of speculative projects, the industry is entering a period of stable growth. An increase in deals between venture capital funds and large pharmaceutical companies seeking new drug development platforms is expected. Capital will flow into areas where science meets algorithms, such as AI-driven drug discovery, synthetic biology and cell therapies.

Another trend is the growing role of state and quasi-state funds. These funds will invest in critical technologies of strategic importance, such as vaccine production, gene therapy and biomaterials. This creates new opportunities for co-financing for private capital.

Where will investors look for growth? Market segments and geographical regions

The greatest growth is expected to occur in areas where biotechnology intersects with digital tools between 2026 and 2027. Investors are focusing on synthetic biology, AI platforms for drug development and personalised medicine. Companies that can reduce the cost of clinical trials through virtual models or biosimulations are of particular interest.

Geographically, centres of growth are shifting. South Korea, Singapore, Israel, and Northern European countries are becoming new biotech hubs. These countries offer a combination of government support, tax incentives, and a highly qualified scientific workforce. Meanwhile, consolidation continues in the US, with major players buying up promising startups at the preclinical stage and giving venture capital funds faster exits.

In terms of technology, investors prefer to expand platforms that can create multiple products based on a single core. This applies not only to pharmaceuticals, but also to agrobiotechnology, protein production and biomaterials. In the coming years, growth will not come from laboratories in isolation, but from ecosystems that combine biology, artificial intelligence and industrial engineering.

In what ways might the structure of VC funds in biotechnology change?

Traditional venture capital funds are increasingly revising their operating models. Biotechnology requires capital, deep expertise, a long-term outlook and partnerships with scientific institutions. By 2026, it is expected that the number of specialised biotech funds with their own scientific advisors, laboratory resources, and platforms to accelerate research will grow.

A new format is emerging in the form of hybrid funds that combine venture capital logic with corporate or government structures. These funds not only invest, but also support startups through to the clinical approval stage. Rather than operating within the traditional 10-year cycle, funds are adopting more flexible investment strategies where funding can be renewed after each proof-of-concept phase.

Funds specialising in specific industries, such as gene therapy or bioinformatics, are also becoming more prevalent. This enables them to assess risks more effectively and expedite the due diligence process. The future of VC in biotechnology lies not in passive capital, but in active participation in the creation of scientific value.

The convergence of biotechnology with AI and other digital technologies and other cross-sector trends

True convergence between bio-innovation and digital technologies will be achieved by 2026. AI is already being used to search for new molecules, predict protein reactions, and model cellular processes. This reduces costs and shortens the time to clinical trials in the early stages of development.

Cross-sector trends extend beyond medicine. Biotechnology is being integrated into energy, agriculture, and materials science. For instance, companies are developing bioenzymes for plastic recycling and biomaterials for batteries. Investors see this as an opportunity to create new markets where biological processes replace traditional chemistry.

AI in biotechnology is no longer just a supporting tool — it is a strategic partner. Bio-digital platforms enable the simultaneous creation of thousands of experimental variations. For venture capitalists, this means increased investment productivity and a faster path to results. The fusion of biology and AI is giving rise to a new discipline — intelligent biology — which will be at the heart of innovation over the next decade.

What will be valued most for startups?

Investors are increasingly turning their attention to startups with a unique technological core that has the potential to create a chain effect. This could be an algorithm, a bioprocess, or a patent library that can be scaled up and applied to dozens of areas.

Teams with a proven scientific reputation and a clear understanding of commercial applications will be particularly highly valued. While the ‘science-first’ approach remains important, business discipline now complements it. Investors want to see proof of concept and a path to profitability.

Startups that integrate digital tools such as AI analytics, laboratory automation and remote data monitoring will have an advantage. These tools enable them to work more efficiently, cheaply and on a larger scale. For venture capital funds, this signals that the future of biotechnology belongs to companies that think like scientists but act like businesses. These players will define the new era of venture capital investment in biotechnology.